Access Course

 

02cd819c-d749-437d-8d08-27368121439f.jpg

Dr. Jonathan Rosenberg reviews the latest evidence on the use of checkpoint inhibitors in bladder cancer.

 

This activity is intended for oncologists, urologists, and nephrologists.

 

The goal of this activity is to review the latest advances in the use of immunotherapy in bladder cancer.

 

 

 

 

Approximate Time to Complete: 30 minutes

 

Course Available Beginning: Mar. 29, 2017

 

Developed through a partnership between SITC and Medscape.

sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
Course Objectives
Upon completion of this activity, participants will be able to:
  • Have increased knowledge regarding the mechanisms of action of emerging immunotherapeutic agents in the treatment of bladder cancer
  • Have increased knowledge regarding the clinical trial data assessing immunotherapeutic agents in the treatment of bladder cancer